mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
复制标题
DOI：
10.1038/s41590-021-01021-0
复制
发表时间：
2021-10
影响因子：
30.5
通讯作者：
Seder RA
中科院分区：
文献类型：
--
作者：
Corbett KS;Werner AP;Connell SO;Gagne M;Lai L;Moliva JI;Flynn B;Choi A;Koch M;Foulds KE;Andrew SF;Flebbe DR;Lamb E;Nurmukhambetova ST;Provost SJ;Bock KW;Minai M;Nagata BM;Ry AV;Flinchbaugh Z;Johnston TS;Mokhtari EB;Mudvari P;Henry AR;Laboune F;Chang B;Porto M;Wear J;Alvarado GS;Boyoglu-Barnum S;Todd JM;Bart B;Cook A;Dodson A;Pessaint L;Steingrebe K;Elbashir S;Sriparna M;Pekosz A;Andersen H;Wu K;Edwards DK;Kar S;Lewis MG;Boritz E;Moore IN;Carfi A;Suthar MS;McDermott A;Roederer M;Nason MC;Sullivan NJ;Douek DC;Graham BS;Seder RA
B.1.351是对抗体中和最有抵抗力的SARS-CoV-2变体。我们演示了免疫接种的剂量和数量如何影响保护。非人灵长类动物（NHP）接种了两剂30或100 μg的Moderna mRNA-1273疫苗，单次接种30 μg，或不接种疫苗。两剂100 μg mRNA-1273诱导的抗活SARS-CoV-2 D614G和B.1.351的平均中和抗体滴度分别为3,300和240。与单次给药相比，两次给药后对B.1.617.2的中和反应也更高。用B.1.351攻击后，两剂量疫苗组的支气管肺泡灌洗液中的病毒亚基因组RNA （sgRNA）减少了~ 4-5 - log10，复制率低至无法检测，100 μg剂量组的鼻拭子（NS）减少了1 - log10。这些数据表明，两剂量的mRNA-1273治疗方案对于提供上呼吸道和下呼吸道保护，防止主要变异至关重要。
B.1.351 is the SARS-CoV-2 variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates (NHP) received two doses of 30 or 100 μg of Moderna’s mRNA-1273 vaccine, a single immunization of 30 μg, or no vaccine. Two doses of 100 μg of mRNA-1273 induced reciprocal ID50 mean neutralizing antibody titers against live SARS-CoV-2 D614G and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. Following challenge with B.1.351, there was ~4–5−log10 reduction of viral subgenomic RNA (sgRNA) and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1−log10 reduction in nasal swabs (NS) in the 100 μg dose group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.
登录
查看更多内容
影响因子：
64.5
作者：
Li Q;Nie J;Wu J;Zhang L;Ding R;Wang H;Zhang Y;Li T;Liu S;Zhang M;Zhao C;Liu H;Nie L;Qin H;Wang M;Lu Q;Li X;Liu J;Liang H;Shi Y;Shen Y;Xie L;Zhang L;Qu X;Xu W;Huang W;Wang Y
通讯作者：
Wang Y
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S
影响因子：
2.1
作者：
Finak, Greg;McDavid, Andrew;Gottardo, Raphael
通讯作者：
Gottardo, Raphael
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1056/nejmoa2102214
发表时间：
2021-05-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Madhi SA;Baillie V;Cutland CL;Voysey M;Koen AL;Fairlie L;Padayachee SD;Dheda K;Barnabas SL;Bhorat QE;Briner C;Kwatra G;Ahmed K;Aley P;Bhikha S;Bhiman JN;Bhorat AE;du Plessis J;Esmail A;Groenewald M;Horne E;Hwa SH;Jose A;Lambe T;Laubscher M;Malahleha M;Masenya M;Masilela M;McKenzie S;Molapo K;Moultrie A;Oelofse S;Patel F;Pillay S;Rhead S;Rodel H;Rossouw L;Taoushanis C;Tegally H;Thombrayil A;van Eck S;Wibmer CK;Durham NM;Kelly EJ;Villafana TL;Gilbert S;Pollard AJ;de Oliveira T;Moore PL;Sigal A;Izu A;NGS-SA Group;Wits-VIDA COVID Group
通讯作者：
Wits-VIDA COVID Group